MRNA stock has a bullish daily structure, but the hourly chart challenges that bias. Moderna trades above its daily exponential averages while sitting below key hourly averages. The distinction matters: the daily framework supports a conditional bullish case, not broad agreement across timeframes.
Key takeaways
- MRNA stock was trading at $212.74 as of 10:40 ET, an intraday move of -10.05% versus the previous close.
- The 20-session EMA is $198.69, the 50-session EMA is $161.94, and the 200-session EMA is $93.2, all below price.
- Daily RSI14 is 59.3, down from 71.72, while the daily MACD histogram is 0.04, down from 1.33.
- Hourly RSI14 is 40.04, below 50, and price sits below the 50-hour EMA at $216.36 and the 20-hour EMA at $224.91.
- Daily ATR14 is $16.85, up from $15.95, with price below daily first support, S1, at $221.58.
On Friday, October 16, 2026, Moderna opened at $234.81 and traded between a low of $208.93 and a high of $237.48. It was trading at $212.74 as of 10:40 ET. The intraday move was -10.05% versus the previous close, with volume of 264,882 shares so far. Opened at $234.81, traded between a low of $208.93 and a high of $237.48, and was last at $212.74, against a previous close of $236.50.
MRNA stock: Daily structure supports a conditional bullish bias
The daily structure supports a conditional bullish bias, with price above its key exponential averages. The 20-session EMA is $198.69, the 50-session EMA is $161.94, and the 200-session EMA is $93.2, all bullishly aligned beneath price. Still, that ordering does not offset the bearish hourly evidence.
However, daily RSI14 fell to 59.3 from 71.72. It is above 50 but no longer in overbought territory. The daily MACD histogram also fell to 0.04 from 1.33. At 19.58, the MACD line is only slightly above its signal at 19.54, leaving little separation between them.
Meanwhile, price sits between the daily Bollinger mid-band at $200.91 and upper band at $232.91. The mid-band is a downside reference, while the upper band marks an overhead hurdle. Daily ATR14 increased to $16.85 from $15.95, indicating greater absolute volatility than in the preceding daily reading.
The daily pivot framework is less supportive. Price is below first support, S1, at $221.58 and the pivot at $231.94. These levels, calculated from the previous completed daily candle, are overhead barriers for the current session.
Hourly signals challenge the daily case
The hourly chart complicates the daily bullish case, with price below the 50-hour EMA at $216.36 and the 20-hour EMA at $224.91. Moderna remains above the 200-hour EMA at $185.62. That arrangement does not provide bullish alignment, despite the daily chart’s ordered averages.
Hourly RSI14 stands at 40.04, below 50. The hourly MACD line is positive at 3.3 but below its signal at 5.46; the histogram is negative at -2.15. Together, those readings run counter to the daily bullish case without establishing a bearish daily trend.
Moreover, price is below the hourly pivot at $219.27 and Bollinger mid-band at $225.22, but above the lower band at $205.86. The hourly chart therefore places several resistance references above the current price.
Short-term timing and the vaccine-news backdrop
The 15-minute chart shows oversold momentum, with RSI14 at 22.67. The MACD line at -4.29 is below its signal at -0.6, with a negative histogram of -3.69. Oversold conditions alone do not establish a bullish entry signal.
For execution context, price sits just above the 15-minute lower Bollinger band at $212.43 and pivot at $212.34. First resistance, R1, is $213.67, followed by the 200-quarter-hour EMA at $214.52. Below price, first support S1 sits at $210.06.
Separately, a Seeking Alpha report published on Thursday, October 15 described bearish analyst views ahead of new late-stage melanoma cancer vaccine trial data. That coverage provides context on the melanoma cancer vaccine trial data.
Bullish and bearish scenarios
The bullish case requires clearing the hourly 50-hour EMA at $216.36, then the hourly pivot at $219.27. A move above daily S1 at $221.58 would add support to that case. The daily pivot at $231.94 and upper Bollinger band at $232.91 would then define further overhead hurdles.
Conversely, a break below the session low at $208.93 would put the hourly lower Bollinger band at $205.86 in focus. Below that, the daily mid-band at $200.91 and 20-session EMA at $198.69 are the next daily references. A sustained break beneath both would invalidate the near-term bullish scenario.
Overall, MRNA stock stands above its daily averages but below daily S1 and key hourly resistance. Daily ATR14 of $16.85 underscores the volatility. The unresolved question is whether those daily supports can hold while the hourly chart lacks bullish confirmation.
FAQ
What is the current MRNA stock price?
MRNA stock was trading at $212.74 as of 10:40 ET on Friday, October 16, 2026. The intraday move was -10.05% versus the previous close, with volume of 264,882 shares so far.
What are the key daily levels for MRNA stock?
The daily 20-session EMA is $198.69, the 50-session EMA is $161.94, and the 200-session EMA is $93.2. Price is below daily first support, S1, at $221.58 and the daily pivot at $231.94.
What does the hourly chart show for MRNA stock?
Hourly RSI14 is 40.04, below 50. Price sits below the 50-hour EMA at $216.36 and the 20-hour EMA at $224.91, but above the 200-hour EMA at $185.62.
What is the bullish scenario for MRNA stock?
The bullish scenario requires price to clear the hourly 50-hour EMA at $216.36, then the hourly pivot at $219.27. A move above daily S1 at $221.58 would add support to that case.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.